NCT04713670View on ClinicalTrials.gov

Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection

PHASE4RecruitingINTERVENTIONAL
Enrollment

1,200

Participants

Timeline

Start Date

March 10, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
H. Pylori Infection
Interventions
DRUG

(A) T-V14

vonoprazan(vocinti)-based triple therapy for 14 days (T-V14)

DRUG

(B) T-V7

vonoprazan(vocinti)-based triple therapy for 7 days (T-V7)

DRUG

(C) D-V14

vonoprazan(vocinti)-based dual therapy for 14 days (D-V14)

DRUG

(D) HD-V14

vonoprazan(vocinti)-based high dose dual therapy for 14 days (HD-V14)

DRUG

(E) BQ-V14

vonoprazan(vocinti)-based bismuth quadruple therapy for 14 days (BQ-V14)

DRUG

(F) RH-V14

vonoprazan(vocinti)-based reverse hybrid therapy for 14 days (RH-V14)

DRUG

(G) BQ-L14

lansoprazole(takepron)-based bismuth quadruple therapy for 14 days (BQ-L14)

DRUG

(H) T-L14

lansoprazole(takepron)-based triple therapy for 14 days (T-L14)

Trial Locations (1)

Unknown

RECRUITING

National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER